
|Videos|April 27, 2023
ARVO LIVE: OTT166 in the treatment of diabetic retinopathy
Author(s)David Hutton, Martin David Harp
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Advertisement
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Increasing the knowledge base of GA is key to individualizing patient therapy
2
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved by FDA
3
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
4
Q&A: Inder Paul Singh, MD, explores technician empowerment via the Academy Technician Training Platform
5